CBS 2019
CBSMD教育中心
中 文

急性冠脉综合征

Abstract

Recommended Article

Clinical Characteristics and Outcomes of STEMI Patients With Cardiogenic Shock and Cardiac Arrest Prognostically relevant periprocedural myocardial injury and infarction associated with percutaneous coronary interventions: a Consensus Document of the ESC Working Group on Cellular Biology of the Heart and European Association of Percutaneous Cardiovascular Interventions (EAPCI) Intravenous Statin Administration During Myocardial Infarction Compared With Oral Post-Infarct Administration Antiplatelet therapy in patients with myocardial infarction without obstructive coronary artery disease Percutaneous Coronary Intervention for Chronic Total Occlusion—The Michigan Experience: Insights From the BMC2 Registry Long-Term Prognostic Implications of Previous Silent Myocardial Infarction in Patients Presenting With Acute Myocardial Infarction Transition of Macrophages to Fibroblast-Like Cells in Healing Myocardial Infarction Efficacy and Safety of Stents in ST-Segment Elevation Myocardial Infarction

Original Research

JOURNAL:CBS2017 Article Link

CBS Insight with Professor Yaling Han

CBS2017 Keywords: CBS Insight; Yaling Han; NeoVas; PSP

CBS Insight interviewed Prof Yaling Han at CBS2017



Biography

Prof. Yaling Han, renowned interventional cardiologist, Academician of Chinese Academy of Engineering since 2013, Director of Institute for Cardiovascular Diseases of PLA, Director of the Key Laboratory of Acute and Severe Cardiovascular Disease of PLA, Director of Cardiology Department of Shenyang Military Region, as well as the President of Chinese College of Cardiovascular Physicians (CCCP), elected Chairperson of Chinese Society of Cardiology (CSC), FACC, FESC. Editor-In-Chief of Chinese Journal of Cadiology, JACC International Advisors, Editorial board of Circulation and the Associate editor of Cardiovascular Therapeutics, Chairperson of Great Wall International Congress of Cardiology (GW-ICC) 2017, Vice Chairperson of Transcatheter Cardiovascular Therapeutics (TCT), Chairperson of Northeast Cardiovascular Forum (NCF). Prof. Han’s major academic contributions and technical expertise are interventional treatment and antithrombotic therapy of complex critical ischemic heart diseases. As principle investigator, prof. Han has led BRIGHT, TRACK-D, I-Love-It 2, CREATE, and other multi-center, large-scale clinical researches, and participated and exchanged her research outcomes at ACC, ESC, TCT, and other important international academic conferences. As first author, prof. Han has obtained 2 items of “Second Class Prize of National Scientific and Technological Progress” and 6 items of “First Class Prize of Military and Liaoning Province”. As corresponding author, Prof. Han has published more than 700 research papers, including the international journals JAMA, JACC, etc.



Reference used in this interview


A randomized trial comparing a novel sirolimus-eluting bioresorbable scaffold with everolimus-eluting metallic stents in patients with coronary artery disease



Remarks


Date of this Interview: Dec 1st, 2017

This video is intended for professional use only by physicians and is not intented for reposting or redistribution on other external channels.

Caution: This product is intended for use by or under the direction of a physician. Prior to use, reference CBS2017.

www.cbs2017.org. All rights reserved.